On January 5, 2026 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported it will present at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. Pacific Time on Monday, January 12, 2026, in San Francisco. Kyle Gano, Chief Executive Officer, will present at the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live presentation will be webcast and can be accessed on Neurocrine Biosciences’ website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

(Press release, Neurocrine Biosciences, JAN 5, 2026, View Source [SID1234661726])

On January 5, 2026 Sanofi K.K. (hereinafter "Sanofi") and Taiho Pharmaceutical Co., Ltd. (hereinafter "Taiho") reported that the sales of the anticancer agent Jevtana I.V. Infusion 60 mg (generic name: cabazitaxel; hereinafter "Jevtana") will be transferred from Sanofi to Taiho in Japan effective April 1, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jevtana is an anticancer agent which was approved and launched in Japan in 2014, indicated for patients with castration-resistant prostate cancer previously treated with a docetaxel-containing regimen. The agent inhibits cell division by promoting tubulin polymerization and stabilizing microtubules, thereby suppressing the proliferation of cancer cells.

On April 1, 2026, Taiho will assume responsibility for the sales and marketing, and medical information activities for Jevtana in Japan, while Sanofi will continue to be the marketing authorization holder and will also continue to manufacture the product.

Sanofi and Taiho remain committed to ensuring a smooth transition and continued supply of Jevtana to patients in need of this treatment.

(Press release, Taiho, JAN 5, 2026, View Source [SID1234661724])

On January 5, 2026 Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, reported that Michael A. Metzger, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 3:00 p.m. PT/ 6:00 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available in the Investor section of the Company’s website at www.syndax.com, where a replay will also be available for a limited time.

(Press release, Syndax, JAN 5, 2026, View Source [SID1234661723])

On January 5, 2026 Star Therapeutics, a late clinical-stage biotechnology company discovering and developing best-in-class antibodies for bleeding disorders and other diseases, reported that Adam Rosenthal, Ph.D., CEO and Founder, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 4:30 p.m. PT in San Francisco, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Rosenthal will provide an overview of the company and its lead program, VGA039, a first-in-class monoclonal antibody therapy that targets Protein S, with dual actions promoting platelet attachment and enhancing fibrin deposition to restore hemostasis. VGA039 has potential to be a universal hemostatic therapy that can treat numerous bleeding disorders, starting with von Willebrand disease (VWD), and is currently being evaluated in a pivotal Phase 3 study for the treatment of VWD. Interim data from the ongoing Phase 1/2 multidose study of VGA039 in VWD were presented at the 67th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting in December 2025, demonstrating substantial bleed reductions in all patients, across all types of VWD and all types of bleeds.

(Press release, Star Therapeutics, JAN 5, 2026, View Source [SID1234661722])

On January 5, 2026 Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, reported that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 10:30 a.m. PT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live webcast of the presentation, please visit: View Source Following the live presentation, a replay will be available on the company’s website for at least 14 days.

(Press release, Revolution Medicines, JAN 5, 2026, View Source [SID1234661721])